Efficacy of Combined Desensitization Therapy Based on Protein A Immunoadsorption on Anti-human Leukocyte Antigen Antibodies in Sensitized Kidney Transplant Recipients: A Retrospective Study

• Published in: Curēus (Palo Alto, CA) Vol. 14; no. 9; p. e28661
• Main Authors: Chen, XiaoFei, Wang, YuXian, Dong, PeiJian, Wang, JiaMei, Yu, XiaoTian, Yu, BoGuang
• Format: Journal Article
• Language: English
• Published: Palo Alto Cureus Inc 01.09.2022; Cureus
• Subjects: Adsorption; Allergy/Immunology; Antibodies; Antigens; Apheresis; Desensitization (Psychology); Immunoglobulins; Ischemia; Kidney transplants; Medical research; Nephrology; Patients; Plasma; Proteins; Surgery; Therapeutics
• ISSN: 2168-8184; 2168-8184
• DOI: 10.7759/cureus.28661

Background and objectivesProtein A immunoadsorption (PA-IA) therapy is an immunoglobulin selective apheresis for pre-transplantation desensitization therapy and treatment of post-transplantation antibody-mediated rejection. There is no unified protocol for the timing of PA-IA therapy or its combination with other drug therapy. This study aimed to investigate and analyze the clearance effects of desensitization therapy on human leukocyte antigen (HLA) antibodies to provide a reference for the formulation of clinical desensitization therapy regimens.Materials and methodsOverall, 27 kidney transplant recipients who received preoperative/postoperative desensitization therapy based on PA-IA therapy in combination with drug therapy were enrolled. The pre-treatment mean fluorescence intensity (MFI) of 1324 human leukocyte antigen (HLA) antibody specificities (MFI >2000) and the post-treatment MFI of the corresponding antibody specificities (after one, four, seven, and 10 sessions) were recorded to analyze the changes in antibody level reduction for the different antibody classes and MFI ranges.ResultsAfter 10 sessions of PA-IA therapy, the MFI of class I antibodies decreased from 8298.56 to 3196.15 (reduction of 66.80%), while the MFI of class II antibodies decreased from 13,521.09 to 2773.29 (reduction of 71.14%). The pre-treatment level of class II antibodies was significantly higher than that of class I antibodies (p<0.001), whereas the post-treatment levels of class I and II antibodies were comparable (p>0.05). The clearance effects of PA-IA therapy were greater for strongly positive (MFI>10,000) class II antibodies than for strongly positive class I antibodies, showing a reduction of 62.59% (25.17% to 91.04%) and 45.13% (32.70% to 73.94%), respectively (p=0.015).ConclusionsWe confirmed the removal efficacy of PA-IA for HLA antibodies. The removal efficacy of class II antibodies on PA-IA is not inferior to that of class I. Under an adequate number of treatment sessions, the clearance effect of PA-IA therapy for strongly positive class II antibodies may be greater than that for strongly positive class I antibodies.